2025-05-14 15:05 | CC:RVX | Resverlogix Corp | 0.045 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2025-05-14 15:05 | CC:RVX | Resverlogix Corp | 0.045 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
2025-03-31 07:05 | CC:RVX | Resverlogix Corp | 0.04 | SEDAR Audited Annual Financial Statements804 | SEDAR Audited Annual Financial Statements |
2025-03-31 07:05 | CC:RVX | Resverlogix Corp | 0.04 | SEDAR MD & A815 | SEDAR MD & A |
2025-03-31 06:59 | CC:RVX | Resverlogix Corp | 0.04 | SEDAR Annual Information Form802 | SEDAR Annual Information Form |
2024-11-12 18:26 | CC:RVX | Resverlogix Corp | 0.065 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2024-11-12 18:26 | CC:RVX | Resverlogix Corp | 0.065 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
2024-09-03 10:16 | CC:RVX | RESVERLOGIX CORP. J | 0.09 | News Release200 | Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024 |
2024-08-14 18:48 | CC:RVX | Resverlogix Corp | 0.065 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2024-08-14 18:48 | CC:RVX | Resverlogix Corp | 0.065 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
2024-07-31 18:42 | CC:RVX | Resverlogix Corp | 0.05 | News Release200 | Resverlogix shareholders approve AGM resolutions |
2024-07-16 10:30 | CC:RVX | Resverlogix Corp | 0.05 | News Release200 | Resverlogix extends $6M (U.S.) debenture to 2026 |